Novavax Inc (NVAX)

[TRUISM]

Novavax, Inc. Analyst Rating Update
FEBRUARY 19, 2015 BY JOE WILLAMS
Click For stafforddaily.com News



Analysts at Zacks have given a Neutral rating on Novavax, Inc. (NASDAQ:NVAX) with a rank of 3. The counter has received an average rating of 1 from 6 brokerage firms. 6 analysts have rated the company as a strong buy.

Novavax, Inc. (NASDAQ:NVAX): The mean short term price target for Novavax, Inc. (NASDAQ:NVAX) has been established at $9.75 per share. The higher price target estimate is at $11 and the lower price target estimate is expected at $7 according to 6 Analyst. The stock price is expected to vary based on the estimate which is suggested by the standard deviation value of $1.41

Company has also disclosed other Insider Buying and Selling activities to the Exchange Commission ., The Securities and Exchange Commission has divulged in a Form 4 filing that the SVP, Manufacturing of Novavax Inc, Hahn Timothy Jon had purchased shares worth of $10,125 in a transaction dated on October 3, 2014. A total of 2,500 shares were purchased at a price of $4.05 per share. The information is based on open market trades at the market prices.Option exercises are not covered.

Novavax, Inc. (NASDAQ:NVAX) : Volatility spiked in the counter of Novavax, Inc. (NASDAQ:NVAX) but the bulls managed to end the day with appreciating gains. The share price opened at $8.82 and hit an intraday high of $9.1; however, hefty profit booking made the counter give up most of its gains and the shares ended the day positively at $9.07, with a gain of 2.83% or 0.25 points. The shares had previously closed at $8.82. The heightened volatility saw the trading volume jump to 4,535,362 shares. The 52-week high of the share price is $9.225 and the company has a market cap of $2,163 million.






TRUTH